Advertisement
Advertisement
bioAffinity Technologies, Inc. (BIAF)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 2.5500 |
| Open | 2.5200 |
| Bid | 2.3600 x 1000 |
| Ask | 2.3900 x 800 |
| Day's Range | 2.3600 - 2.5100 |
| 52 Week Range | 1.3100 - 15.5500 |
| Volume | |
| Avg. Volume | 1,333,909 |
| Market Cap | 19.92M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for BIAF
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- bioAffinity Technologies, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.RatingFair ValueEconomic MoatyesterdayMorningstar
- Business Wire
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
SAN ANTONIO, January 24, 2023--bioAffinity Technologies announces publication of the results of its clinical trial for its CyPath® Lung cancer diagnostic in Respiratory Research.
- Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
SAN ANTONIO, January 04, 2023--bioAffinity Technologies received Notice of Allowance for a U.S. patent protecting novel compounds for specific delivery of cancer treatments.
- PR Newswire
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
